These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 66171)

  • 1. Using antiandrogen therapy in benign prostatic hypertrophy.
    Geller J; Adler EH; Albert J; Brown DW; Licudan A; Manaig E
    Geriatrics; 1977 Apr; 32(4):63-7, 71. PubMed ID: 66171
    [No Abstract]   [Full Text] [Related]  

  • 2. Megestrol acetate in treatment of benign prostatic hypertrophy.
    Donkervoort T; Zinner NR; Sterling AM; Donker PJ; Van Ness J; Ritter RC
    Urology; 1975 Nov; 6(5):580-7. PubMed ID: 52933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Action of the combination of hypothalamic phospholipids and megestrol acetate (IP 11) in prostatic hypertrophy. Results of a controlled clinical trial].
    Mazza G; Petracco S
    Minerva Urol; 1974; 26(6):293-300. PubMed ID: 4142804
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of megestrol acetate on uroflow rates in patients with benign prostatic hypertrophy: double-blind study.
    Geller J; Nelson CG; Albert JD; Pratt C
    Urology; 1979 Nov; 14(5):467-74. PubMed ID: 92091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gestagens--an effective conservative treatment of the so-called prostatic hypertrophy?].
    Reichelt H
    Wien Med Wochenschr; 1970 Nov; 120(45):792-5. PubMed ID: 4103896
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical studies on morphological changes in the prostate in patients with benign prostatic hypertrophy after antiandrogen therapy--by means of transrectal ultrasonotomography].
    Suzuki K; Ichinose Y; Hashimoto K; Matsumoto K; Suzuki T; Imai K; Yamanaka H
    Hinyokika Kiyo; 1990 May; 36(5):557-60. PubMed ID: 1698012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A controlled clinical trial of aldactone-A in the treatment of benign prostatic hyperplasia.
    Castro JE; Griffiths HJ; Edwards DE; Shackman R
    Br J Surg; 1969 Aug; 56(8):632. PubMed ID: 4185036
    [No Abstract]   [Full Text] [Related]  

  • 8. A study of endocrine function in the treatment of benign prostatic hypertrophy with megestrol acetate.
    Lebech PE; Nordentoft EL
    Acta Obstet Gynecol Scand; 1967; 46(S9):25-38. PubMed ID: 4169449
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of cernilton in the treatment of the benign prostatic hypertrophy].
    Horii A; Iwai S; Maekawa M; Tsujita M
    Hinyokika Kiyo; 1985 Apr; 31(4):739-46. PubMed ID: 2412423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Studies using synthetic progestogens in drug therapy of so-called prostatic hypertrophy].
    Scultéty S; Sas M; Varga B
    Z Urol Nephrol; 1973 Jan; 66(1):49-59. PubMed ID: 4121364
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination].
    Hausmann R; Thalmann G; Reich O; Steif CG
    Aktuelle Urol; 2004 Sep; 35(5):339-42. PubMed ID: 15383991
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical effect of allylestrenol on benign prostatic hypertrophy].
    Tajima A; Aso Y; Ushiyama T; Hata M; Kambayashi T; Ohmi Y; Masuda H; Nakahara M; Kitagawa M; Suzuki A
    Hinyokika Kiyo; 1986 Mar; 32(3):477-85. PubMed ID: 2425610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug treatment of prostatic hypertrophy].
    Sökeland J; Bressel M
    Dtsch Med Wochenschr; 1966 Nov; 91(44):1982-4. PubMed ID: 4163463
    [No Abstract]   [Full Text] [Related]  

  • 15. [Medical treatment of fibroadenomatous hypertrophy of the prostate with a new plant substance].
    Maver A
    Minerva Med; 1972 May; 63(37):2126-36. PubMed ID: 4113157
    [No Abstract]   [Full Text] [Related]  

  • 16. When to investigate benign prostatic hyperplasia.
    Thomas D
    Practitioner; 1997 Jul; 241(1576):408-13. PubMed ID: 9425714
    [No Abstract]   [Full Text] [Related]  

  • 17. [Gestonorone therapy of prostatic adenoma].
    Lopatkin N; Darenkow A; Sahmatow J; Tankó A; Ignaschin N; Warentsow G
    Acta Chir Acad Sci Hung; 1980; 21(4):271-8. PubMed ID: 6175122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications.
    Fine SR; Ginsberg P
    J Am Osteopath Assoc; 2008 Jul; 108(7):333-7. PubMed ID: 18648026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Amino acid therapy for hypertrophy of the prostate].
    Shiga H; Kumamoto E; Imamura A
    Hinyokika Kiyo; 1968 Aug; 14(8):625-32. PubMed ID: 4178205
    [No Abstract]   [Full Text] [Related]  

  • 20. Benign prostatic hypertrophy: update on drug therapy.
    Tejani A; Musini V; Perry TL; Mintzes B; Wright JM
    Can Fam Physician; 2006 Sep; 52(9):1075-6, 1077-8. PubMed ID: 17279217
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.